Cryoport Unveils 32-Inch Fusion 800 Storage System, Raises FY25 Revenue Outlook
Cryoport's MVE Biological Solutions division has introduced the Fusion 800 Series, a 32-inch-wide cryogenic storage system that operates without continuous liquid nitrogen and fits through standard door frames to reduce facility modification costs and operational complexity. In Q3, Cryoport generated $44.2 million in revenue—beating estimates—and posted an 18-cent loss per share while raising FY25 revenue guidance to $170–$174 million.
1. Fusion 800 Series Launch
Cryoport’s MVE Biological Solutions division has unveiled the Fusion 800 Series, marking its latest advance in cryogenic storage solutions. The system’s debut underscores the company’s focus on modernizing storage infrastructure for biological materials and life-science applications.
2. Design and Operational Benefits
The Fusion 800 operates without continuous liquid nitrogen, eliminating refilling demands and enhancing safety. At just 32 inches wide, it fits through standard door frames to avoid costly facility modifications while supporting high-volume storage with reduced operational complexity.
3. Q3 Financial Performance
In its third quarter, Cryoport reported $44.2 million in revenue, surpassing analyst estimates of $41.36 million, and posted a loss of $0.18 per share versus an expected $0.21 loss. Commercial Cell and Gene Therapy revenue jumped 36% year over year, while Life Sciences Services and Products grew 16% and 15%, respectively.
4. FY25 Revenue Guidance Raise
Following the strong Q3 beat and robust segment growth, Cryoport increased its fiscal 2025 revenue guidance to $170 million–$174 million. This outlook adjustment reflects management’s confidence in sustaining momentum driven by new product adoption and growing service demand.